Bicyclic pyrazoles as protein kinase inhibitors

A compound of formula (I):

• wherein:
• X is CH or N;
• R1 is hydrogen, halogen, NR7R8, NHCOR9, SR10 or SO2R10, wherein:
• R7 and R8 are, each independently one from the other, hydrogen, or a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl,
• heterocyclyl, aryl and heteroaryl, or R7 and R8 taken together may form a phthalyl group,
• R9 is OR10, NR11R12 or a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl or (C2-C8) alkynyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl,
• R10 is a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl, R11 and R12 are, each independently one from the other, hydrogen or a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl, or taken together with the nitrogen atom to which they are bonded R11 and R12 may form an optionally substituted 3 to 8 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH;
• R2, R3, R4 and R5 are, each independently one from the other, hydrogen, halogen, trifluoromethyl, trichloromethyl, cyano, OR13 or a group optionally substituted selected from straight or branched (C1-C8) alkyl, and (C3-C8) cycloalkyl, wherein:
• R13 is hydrogen or a group optionally substituted selected from straight or branched (C1-C8) alkyl and (C3-C8) cycloalkyl;
• A is —O—, —CON(Y)—, —CON(Y)O—, —CON(Y)N(Y)—, —CON(Y)SO2—, —SO2N(Y)—, —SO2N(Y)O—, —SO2N(Y)N(Y)—, —SO2N(Y)CO—, —SO2N(Y)CON(Y)—, —SO2N(Y)SO2—, —N(Y)CO—, —N(Y)SO2—, —N(Y)CON(Y)—, —N(Y)CSN(Y)—, —N(Y)CON(Y)N(Y)—, —N(Y)COO—, —N(Y)CON(Y)SO2—, —N(Y)SO2N(Y)—, —C(R′R″)CON(Y)—, —C(R′ R″)CSN(Y)—, —C(R′R″)CON(Y)O—, —C(R′ R″)CON(Y)N(Y)—, —C(R′R″)CON(Y)SO2—, —C(R′R″)SO2N(Y)—, —C(R′R″)SO2N(Y)O—, —C(R′R″)SO2N(Y)N(Y)—, —C(R′R″)SO2N(Y)CO—, —C(R′R″)SO2N(Y)SO2—, —C(R′R″)N(Y)CO, —C(R′R″)N(Y)SO2—, —C(R′R″)N(Y)CON(Y)—, —C(R′R″)N(Y)CSN(Y)—, C(R′R″)N(Y)COO— or —C(R′R″)N(Y)SO2N(Y)—, wherein:
• Y is hydrogen or an optionally substituted straight or branched (C1-C3) alkyl;
• and R′ and R″ are, each independently one from the other, hydrogen or an optionally further substituted straight or branched (C1-C6) alkyl, or taken together with the carbon atom to which they are bonded R′ and R″ may form an optionally substituted (C3-C8) cycloalkyl;
• R6 is hydrogen or an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl , (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl;
• m is an integer from 0 to 2;
• W is (CH2)n, wherein n is an integer from 2 to 4, CH(R14)-CH(R15) or C(R14)=C(R15), wherein
• R14 and R15 are, each independently one from the other, hydrogen or a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl, or R14 is hydrogen and R15 is COR16, or R15 is hydrogen and R14 is COR16, wherein:
• R16 is OR17, NR18R19 or a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl or (C2-C8) alkynyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein:
• R17 is hydrogen or a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl;
• R18 and R19 are, each independently one from the other, a hydrogen, a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl, or taken together with the nitrogen atom to which they are bonded R18 and R19 may form an optionally substituted 3 to 8 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH;
• and pharmaceutically acceptable salts thereof.